Annual Report

Overview

The report describes a strong 2021 performance, with Group revenue rising 11.7% to RMB27,867 million and profit attributable to shareholders increasing 8.6% to RMB5,605 million. It also highlights continued investment in pharmaceutical R&D, with expenses reaching RMB3,433 million and a broad pipeline of innovative medicines. The company reports that its MSCI ESG rating improved from BBB to A during 2021.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2021
Period: Ends 31 December 2021
Publication date: 22 March 2022
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services